Clinical trial NCT00418093 (phase 2, status: terminated)
Conditions: ovarian cancer, fallopian tube cancer, primary peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: gemcitabine, oxaliplatin, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    the study was terminated early due to a lack of accural
  
Eligibility criteria:

        Inclusion Criteria:

          -  Recurrent ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic or
             cytologic confirmation of the original primary tumor is required.

          -  Must have measurable disease which is defined as at least one lesion that can be
             accurately measured in at least one dimension. Each lesion must be >20mm when measured
             by conventional techniques.

          -  Must have at least one "target lesion" to be used to assess response.

          -  Platinum-sensitive tumors, defined as a platinum free interval of at least 6 months,
             and may have had up to two prior treatment regimens.

          -  Eastern Cooperative Oncology Group score of 0 or 1

          -  Life expectancy of 12 weeks or longer

          -  18 years of age or older

          -  Adequate bone marrow, renal, neurologic and liver function

          -  Normal blood coagulation parameters

        Exclusion Criteria:

          -  Chemotherapy within last 3 weeks

          -  Current, recent (within 4 weeks), or planned participation in an experimental drug
             study other than a Genentech-sponsored bevacizumab cancer study.

          -  Known bleeding disorder or coagulopathy, or history of stroke.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study entry or the anticipation of need for major surgical procedure during
             the course of the study.

          -  Minor surgical procedures within 14 days of study entry.

          -  Significant cardiovascular disease, New York Heart Association Grade II or greater
             congestive heart failure, serious cardiac arrhythmia requiring medication, a history
             of deep vein thrombosis, or Grade II or greater, clinically significant peripheral
             vascular disease within 1 year of study entry.

          -  Urine protein:creatinine ration greater than or equal to 1.0

          -  History or clinical evidence of central nervous system disease

          -  Patients with other invasive malignancies, with the exception of non-melanoma skin
             cancer, who have evidence of disease within last three years.

          -  More than 2 prior lines of chemotherapy

          -  Previous treatment with a VEGF targeted inhibitor or antibody

          -  Serious non-healing wound, ulcer or bone fracture

          -  Prior radiation therapy to more than one-third of hematopoietic sites.

          -  History of abdominal fistulas, gastrointestinal perforation, intra-abdominal abscess,
             or partial bowel obstruction within 6 months

          -  Pregnant or lactating